Masui T, Ito T, Komoto I, et al. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20(1):1104.

Article  PubMed  PubMed Central  Google Scholar 

Zheng R, Zhao H, An L, et al. Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States. Chin Med J (Engl). 2023;136(10):1216–24.

PubMed  Google Scholar 

Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104(1):26–32.

Article  PubMed  CAS  Google Scholar 

Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–13.

Article  PubMed  CAS  Google Scholar 

Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556–7.

PubMed  Google Scholar 

Alonso-Gordoa T, Manneh R, Grande E, et al. High-dose somatostatin analogs for the treatment of neuroendocrine neoplasms: where are we now? Curr Treat Options Oncol. 2022;23(7):1001–13.

Article  PubMed  Google Scholar 

Cho MY, Kim JM, Sohn JH, Gastrointestinal Pathology Study Group of Korean Society of Pathologists, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000–2009: Multicenter Study. Cancer Res Treat. 2012;44(3):157–65.

Article  PubMed  PubMed Central  Google Scholar 

Del Rivero J, Perez K, Kennedy EB, et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023;41(32):5049–67.

Article  PubMed  Google Scholar 

Oberg K, Akerström G, Rindi G, et al. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v223–7.

Article  PubMed  Google Scholar 

Salek N, Shirvani Arani S, Bahrami Samani A, et al. Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP. Australas Phys Eng Sci Med. 2018;41(1):69–79.

Article  PubMed  Google Scholar 

Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752–63.

Article  PubMed  CAS  Google Scholar 

Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel). 2019;12(3):114.

Article  PubMed  CAS  Google Scholar 

Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807–17.

Article  PubMed  CAS  Google Scholar 

Ichikawa Y, Kobayashi N, Takano S, et al. Neuroendocrine tumor theranostics. Cancer Sci. 2022;113(6):1930–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim SJ, Pak K, Koo PJ, et al. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(13):1964–70.

Article  PubMed  CAS  Google Scholar 

Dannoon SF, Alenezi SA, Elgazzar AH. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nucl Med Commun. 2017;38(12):1085–93.

Article  PubMed  Google Scholar 

Ahmadi Bidakhvidi N, Goffin K, Dekervel J, et al. Peptide receptor radionuclide therapy targeting the somatostatin receptor: basic principles, clinical applications and optimization strategies. Cancers (Basel). 2021;14(1):129.

Article  PubMed  Google Scholar 

McClellan K, Chen EY, Kardosh A, et al. Therapy resistant gastroenteropancreatic neuroendocrine tumors. Cancers (Basel). 2022;14(19):4769.

Article  PubMed  CAS  Google Scholar 

Ballal S, Yadav MP, Damle NA, et al. Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study. Clin Nucl Med. 2017;42(11):e457–66.

Article  PubMed  Google Scholar 

Ilett EE, Langer SW, Olsen IH, et al. Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review. Diagnostics (Basel). 2015;5(2):119–76.

Article  PubMed  CAS  Google Scholar 

Bodei L, Kwekkeboom DJ, Kidd M, et al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46(3):225–38.

Article  PubMed  Google Scholar 

Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183–90.

Article  PubMed  CAS  Google Scholar 

Severi S, Grassi I, Nicolini S, et al. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Roosenburg S, Laverman P, van Delft FL, et al. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids. 2011;41(5):1049–58.

Article  PubMed  CAS  Google Scholar 

Gotthardt M, Béhé MP, Grass J, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer. 2006;13(4):1203–11.

Article  PubMed  Google Scholar 

Pouget JP, Navarro-Teulon I, Bardiès M, et al. Clinical radioimmunotherapy–the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720–34.

Article  PubMed  CAS  Google Scholar 

Salih S, Alkatheeri A, Alomaim W, et al. Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules. 2022;27(16):5231.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Song H, Sgouros G. Alpha and beta radiation for theragnostics. PET Clin. 2024;19(3):307–23.

Article  PubMed  Google Scholar 

Al-Toubah T, Sikaria D, Jesurajan J, et al. Comparison of nausea and vomiting associated with amino acid formulations coinfused with peptide receptor radionuclide therapy: commercial parenteral nutrition formulas versus compounded arginine/lysine. Pancreas. 2021;50(4):513–5.

Article  PubMed  CAS  Google Scholar 

Kesavan M, Turner JH. Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience. Cancer Biother Radiopharm. 2016;31(6):189–98.

PubMed  CAS  Google Scholar 

Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106–19.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ballal S, Yadav MP, Tripathi M,et al. Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study. J Nucl Med. 2022:jnumed.122.264043.

Demirci E, Alan Selçuk N, Beydağı G, et al. Initial findings on the use of [225Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors. Mol Imaging Radionucl Ther. 2023;32(3):226–32.